Tandem and Dexcom Launch G7 Compatible t:slim X2 Insulin Pump in Canada

Tandem Diabetes Care and Dexcom announced the updated t:slim X2 insulin pump software. It is compatible with Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems and is authorized for sale by Health Canada. 

 

“This integration marks the first time an AID system in Canada is compatible with both Dexcom G7 and Dexcom G6 CGMs, demonstrating our commitment to continued leadership in advancing AID systems and offering choice,” said Mark Novara, executive vice president and chief commercial officer of Tandem Diabetes Care. “We are proud to celebrate more than 10 years of partnership with Dexcom through this milestone that allows users in Canada to benefit from our #1 recommended insulin pump brand, now with Dexcom’s most advanced CGM technology.”

 

The updated t:slim X2 comes with Control-IQ technology using Dexcom CGM data to predict glucose levels 30 minutes ahead and automatically adjust insulin, if needed, to help prevent highs and lows. 

 

It also features customizable Personal Profiles and optional settings for Sleep Activity or Exercise Activities that adjust the range of treatment values as well as a variety of on-body infusion sets that allow users to temporarily disconnect from their pump for convenience and provide the flexibility of more than 30 mix-and-match infusion set and tubing length combinations.

 

“Studies have shown that an AID system powered by Dexcom CGM allows people with diabetes to experience more time in range and can help users reduce nighttime lows,”¹ said André Côté, executive vice president and general manager of Dexcom Canada. “Sensor accuracy is key to automated insulin delivery, and we are thrilled that Canadians using the t:slim X2 insulin pump with Control-IQ technology will soon be able to benefit from integration with Dexcom G7, our smallest and most accurate CGM². This milestone underscores the shared commitment between Dexcom and Tandem to provide cutting-edge technology that empowers individuals with diabetes to live better and feel better every day.”

 

Dexcom G7 users benefit from more time in a closed loop with a 30-minute sensor warmup time; a 12-hour grace period to replace finished sensors for a more seamless transition between sessions and flexibility for when to change sensors; and increased connectivity that Dexcom G7 offers with leading digital health apps.

 

Commercial availability is expected to begin this fall. Tandem will email instructions to all users in Canada with an in-warranty t:slim X2 pump to offer the option to choose between Dexcom G7 and Dexcom G6 via a free remote software update. New customers will receive t:slim X2 pumps pre-loaded with the updated software.

1 Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1701-1717. doi: 10.1056/NEJMoa1907863.

2 Dexcom, Data on File, 2023.